Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. (Q35946094)

11 August 2017

Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. (English)

1 reference

11 August 2017

0 references

1 reference

Li-Yan Khor

1

1 reference

11 August 2017

Michelle Desilvio

2

1 reference

11 August 2017

Rile Li

3

1 reference

11 August 2017

Timothy J McDonnell

4

1 reference

11 August 2017

M Elizabeth H Hammond

5

1 reference

11 August 2017

William T Sause

6

1 reference

11 August 2017

Miljenko V Pilepich

7

1 reference

11 August 2017

Paul Okunieff

8

1 reference

11 August 2017

Howard M Sandler

9

1 reference

11 August 2017

Alan Pollack

10

1 reference

11 August 2017

language of work or name

English

0 references

publication date

11 July 2006

1 reference

International Journal of Radiation Oncology Biology Physics

11 August 2017

1 reference

11 August 2017

66

1 reference

11 August 2017

1

1 reference

11 August 2017

25-30

1 reference

Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

24 September 2018

Bcl-2 family proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1950741

Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer

24 September 2018

1 reference

12 December 2020

Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation

1 reference

12 December 2020

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610

1 reference

12 December 2020

Apoptosis in prostate cancer: bax correlation with stage

1 reference

12 December 2020

Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy

1 reference

12 December 2020

Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma

1 reference

12 December 2020

Immunohistochemical Analysis of Radical Prostatectomy Specimens After 8 Months of Neoadjuvant Hormonal Therapy

1 reference

12 December 2020

The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma

1 reference

12 December 2020

Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation

1 reference

12 December 2020

Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma

1 reference

12 December 2020

bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer

1 reference

12 December 2020

Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10

1 reference

12 December 2020

Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy

1 reference

12 December 2020

10.1016/J.IJROBP.2006.03.056

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

1 reference